DISAPPOINTING TRIAL RESULTS PROMPTS WARNING FROM BIOTECH COMPANY
July 10, 2017MIS416, a potential therapy for secondary progressive MS, has recently finished undergoing phase 2 trials here in Australia and New Zealand. Now Innate Immunotherapeutics, the New Zealand biotech company behind this therapy, has announced the disappointing preliminary top-line results of the trials to their investors. To read more, click on the link below:
DISAPPOINTING TRIAL RESULTS PROMPTS WARNING FROM BIOTECH COMPANY
Article courtesy of MS Research Australia www.msra.org.au